Great Lakes Advisors LLC Has $927,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Great Lakes Advisors LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,565 shares of the biopharmaceutical company’s stock after buying an additional 256 shares during the quarter. Great Lakes Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $927,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Ellevest Inc. grew its stake in Alnylam Pharmaceuticals by 31.7% in the 1st quarter. Ellevest Inc. now owns 915 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 220 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Alnylam Pharmaceuticals by 9.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,604,858 shares of the biopharmaceutical company’s stock worth $226,590,000 after purchasing an additional 140,769 shares during the last quarter. Daiwa Securities Group Inc. grew its position in Alnylam Pharmaceuticals by 44.3% in the 1st quarter. Daiwa Securities Group Inc. now owns 7,813 shares of the biopharmaceutical company’s stock worth $1,103,000 after purchasing an additional 2,399 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Alnylam Pharmaceuticals by 1.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,331 shares of the biopharmaceutical company’s stock worth $3,718,000 after purchasing an additional 351 shares during the last quarter. Finally, MUFG Americas Holdings Corp grew its position in Alnylam Pharmaceuticals by 27.3% in the 1st quarter. MUFG Americas Holdings Corp now owns 1,240 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 266 shares during the last quarter. Institutional investors and hedge funds own 92.35% of the company’s stock.

Shares of ALNY stock opened at $135.70 on Monday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $119.29 and a 12-month high of $178.41. The company has a market capitalization of $15.95 billion, a P/E ratio of -17.33 and a beta of 1.47. The firm has a 50-day moving average price of $137.40 and a 200 day moving average price of $141.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, April 28th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 222.19% and a negative return on equity of 65.96%. During the same quarter in the prior year, the company posted ($1.62) earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.32 earnings per share for the current year.

ALNY has been the topic of several research analyst reports. Royal Bank of Canada restated a “hold” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, February 14th. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $206.00 to $205.00 and set an “overweight” rating on the stock in a research report on Thursday, May 6th. HC Wainwright raised their price target on shares of Alnylam Pharmaceuticals from $225.00 to $235.00 and gave the stock a “buy” rating in a research report on Friday, February 12th. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $162.00 to $196.00 and gave the stock an “overweight” rating in a report on Friday, February 12th. Finally, Citigroup downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $170.00 to $175.00 in a report on Friday, February 12th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $168.73.

In other Alnylam Pharmaceuticals news, insider Akshay Vaishnaw sold 3,706 shares of the firm’s stock in a transaction dated Monday, April 19th. The shares were sold at an average price of $137.67, for a total value of $510,205.02. Following the completion of the sale, the insider now owns 22,908 shares in the company, valued at approximately $3,153,744.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Recommended Story: Most Active Stocks

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.